Diabetes breakthrough 2021. Moderna vaccine 96 percent effective in year-olds, study shows
Two-thirds of the 3, participants in trials in the United States received the vaccine and one-third were given a placebo.
HUN ENG Hormonrezisztenciák lehetséges közös oka és annak feltételezett szerepe a metabolikus szindróma, illetve a cardiovascularis betegségek kialakulásában A possible common cause of hormone resistances and its proposed role in the development of metabolic syndrome and cardiovascular diseases Wittmann István dr.
Tests detected 12 cases of coronavirus 14 days after the first shot. For these intermediate results, participants were followed up on average 35 days after the second injection.
The pharmaceutical company said that any side effects had been "mild or moderate in severity," most commonly pain at the injection site. With the second shot, side effects included "headache, fatigue, myalgia and chills," similar to those observed in adults who had received the vaccine.
Moderna said it is currently "in discussions with regulators about a potential amendment to its regulatory filings" to authorize the vaccine for this age group. It is currently only certified for people aged 18 and over in countries where it has already been approved.
Pfizer and BioNTech have already applied for authorization of their own vaccine for year olds in the United States and Europe. On Wednesday, Canada became the first country to authorize the Pfizer shot for this age group.
The artificial pancreas: a bridge to a cure
The vaccination of teens is the next step in the campaign to eventually contain the epidemic. Moderna also began trials of its vaccine in children aged six months to 11 years in March.
Pfizer and BioNTech announced on Tuesday that they hope to diabetes breakthrough 2021 an emergency authorization request for their vaccine for children aged two to 11 in September in the United States.
Pfizer CEO Albert Bourla said the company could apply for authorization to inoculate children aged between from 6 months and two years "in the fourth quarter. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission.
The content is provided for information purposes only.